Mark E. Bunnage sold $1.8M of Vertex Pharmaceuticals Incorporated (VRTX)

Executed Feb 17, disclosed Feb 19, 2 days later.

Value, as filed

$1.8M

3,619 sh across 2 lots

Executed

Feb 17

the trade date, as filed

Disclosed

Feb 19

2 days after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

–

purchases only

Returns are measured on stock purchases only.

The filer

MB Mark E. Bunnage EVP, Chief Scientific Officer profile →

Mark E. Bunnage (EVP, Chief Scientific Officer) filed 3 Form 4 reports in the trailing twelve months (0 purchases, 3 sales), most often in Vertex Pharmaceuticals Incorporated (VRTX). The largest single filing was $1.8M of VRTX (3,619 sh across 2 lots, as filed), executed Feb 17.

The name

VRTX Vertex Pharmaceuticals Incorporated VRTX · Healthcare · 90 filings in 24 months ticker →

Healthcare · Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→

Other filings by Mark E. Bunnage in VRTX

VRTXSALE Vertex Pharmaceuticals Incorporated $302K
620 sh × $486.35
Exec Feb 25
Filed Feb 26 · 5:30 PM ET VRTXSALE Vertex Pharmaceuticals Incorporated $931K
2,021 sh × $460.43
Exec Feb 11
Filed Feb 12 · 5:30 PM ET